Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MediWound Ltd. (NASDAQ: MDWD).

Full DD Report for MDWD

You must become a subscriber to view this report.


Recent News from (NASDAQ: MDWD)

MediWound to Host Third Quarter 2018 Financial Results Conference Call on November 13 at 8:30 a.m. Eastern Time
YAVNE, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the ...
Source: GlobeNewswire
Date: November, 07 2018 16:05
NexoBrid® Receives Marketing Authorization from Russia's Ministry of Health
Commercial launch is expected in the first half of 2019 YAVNE, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announc...
Source: GlobeNewswire
Date: September, 05 2018 07:00
MediWound to Present at 13th Annual Wells Fargo Securities Healthcare Conference
YAVNE, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will present a corporate overview at the 1...
Source: GlobeNewswire
Date: September, 04 2018 08:00
MediWound Ltd. (MDWD) CEO Gal Cohen on Q2 2018 Results - Earnings Call Transcript
MediWound Ltd. (MDWD) Q2 2018 Results Conference Call August 07, 2018 08:30 AM ET Executives Jeremy Feffer - Managing Director, LifeSci Advisors Steve Wills - Chairman of the Board Gal Cohen - President and CEO Sharon Malka - Chief Financial and Operation Officer Analysts ...
Source: SeekingAlpha
Date: August, 10 2018 22:14
MediWound beats by $0.05, beats on revenue
MediWound (NASDAQ: MDWD ): Q2 EPS of -$0.15 beats by $0.05 . More news on: Mediwound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 07 2018 07:11
MediWound Reports Second Quarter 2018 Financial Results
Completion of enrollment of Phase 3 DETECT Study of NexoBrid ®   Strategic discussions advancing with multiple parties Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 07, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrate...
Source: GlobeNewswire
Date: August, 07 2018 07:00
MediWound to Host Second Quarter 2018 Financial Results Conference Call on August 7 at 8:30 a.m. Eastern Time
YAVNE, Israel, July 31, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the s...
Source: GlobeNewswire
Date: July, 31 2018 08:00
MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.
Study fully funded by BARDA YAVNE, Israel, June 19, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its NexoBri...
Source: GlobeNewswire
Date: June, 19 2018 07:00
MediWound completes enrollment in late-stage study of NexoBrid
MediWound (NASDAQ: MDWD ) completes the enrollment of 175 subjects in its Phase 3 DETECT study assessing NexoBrid in severe burn and wound management. Topline results should be available by year-end. More news on: Mediwound Ltd., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: June, 11 2018 08:06
MediWound Completes Enrollment in NexoBrid® U.S. Phase 3 DETECT Study
Top-line acute data currently expected around year end 2018 YAVNE, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announc...
Source: GlobeNewswire
Date: June, 11 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-086.306.406.556.3031,922
2018-05-176.256.506.655.1562,757
2017-11-154.254.354.504.22271,645
2017-11-144.304.254.354.1550,164
2017-11-134.604.304.604.2594,432

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-111009,0861.1006Cover
2018-12-109,11817,76851.3170Short
2018-12-077003,85018.1818Cover
2018-12-068,11618,09744.8472Short
2018-12-048,70111,15278.0219Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MDWD.


About MediWound Ltd. (NASDAQ: MDWD)

Logo for MediWound Ltd. (NASDAQ: MDWD)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $160,934,035 - 05/11/2018
  • Issue and Outstanding: 27,047,737 - 12/31/2017

 


Recent Filings from (NASDAQ: MDWD)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 10 2018
Annual and transition report of foreign private issuers under sections 13 or 15(d)
Filing Type: 20-FFiling Source: edgar
Filing Date: March, 19 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 19 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 19 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 06 2018

 

 


Daily Technical Chart for (NASDAQ: MDWD)

Daily Technical Chart for (NASDAQ: MDWD)


Stay tuned for daily updates and more on (NASDAQ: MDWD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MDWD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MDWD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MDWD and does not buy, sell, or trade any shares of MDWD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/